- H.C. Wainwright initiated reporting SQZ Biotechnologies Company SQZ with a buy recommendation and a Price target of $10.
- SQZ is focused on developing novel therapeutic cell therapy platforms around the Company’s Cell Squeeze technology.
- The analyst writes that there is significant potential for Cell Squeeze technology in many disease areas and oncological indications.
- The likely next target in oncology is KRAS G12D and/or G12V mutations given positive preclinical results showing that antigen-specific CD8+ T cells were more potent than the active control.
- The company’s pipeline currently consists of four cell therapy platforms.
- The Antigen Presenting Cell (APC) platform is the furthest in development, with initial proof-of-concept data achieved in collaboration with Roche Holding Ltd RHHBYwhich gives credibility to the technology.
- The Enhanced APC (eAPC) platform enhances the APC platform.
- The activating antigen carrier (AAC) platform consists of engineered red blood cells (RBCs) using cell squeeze technology to contain tumor-specific antigens.
- The Tolerizing Antigen Carrier (TAC) platform induces antigen-specific immune tolerance in vivo using a similar approach as the AAC platform; the initial indication is celiac disease (IND expected 1H23).
- The APC program will have updated data and the eAPC and AAC programs will have initial data in Q4 22, creating several potential significant catalysts before year-end.
- Price promotion: SQZ shares are up 6.74% to $3.01 on the last check Thursday.
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
